Press Releases

 
Press Releases
  Date Title and Summary View
Oct 10, 2017
NOVATO, Calif., TOKYO and LONDON, Oct. 10, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) and Kyowa Kirin International PLC (Kyowa Kirin Internati...
Oct 3, 2017
Ultragenyx Enters into Definitive Agreement to Acquire Dimension for $6.00 Per Share in Cash in a Transaction Valued at Approximately $151 Million Based on Currently Outstanding Shares Combined Company will be Strongly Positioned to Bring Needed New Therapies to MarketĀ  NOV...
Oct 2, 2017
NOVATO, Calif., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) ("Ultragenyx" or the "Company"), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today commented on the determination by the Dimension Therapeutics, Inc. (NASDAQ:DMTX) ("Dime...
Sep 18, 2017
Proposed Combination of Complementary Rare Disease Franchises Maximizes the Ability to Bring Needed New Therapies to Market Proposal Delivers Superior Value To Dimension's Shareholders Relative to the REGENXBIO Transaction; Provides Dimension Shareholders with Immediate Cash Pre...
Sep 11, 2017
NOVATO, Calif. and TOKYO, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) today announced positive data from two ongoing Phase 2 studie...
Sep 6, 2017
NOVATO, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Shalini Sharp, the company's Chief Financial Officer, will present at the Morgan Stanley 15th ...
Aug 31, 2017
NOVATO, Calif., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Baird 2017 Global...
Aug 24, 2017
NOVATO, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced upcoming presentations of data highlighting burosumab for the treatment of X-linked hypophosphatemia (XLH) and ...
Aug 24, 2017
NOVATO, Calif. and TOKYO, Aug. 24, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) today announced that Ultragenyx has submitted a Biologics Lice...
Aug 22, 2017
NOVATO, Calif., Aug. 22, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that a Phase 3 study evaluating aceneuramic acid extended release (Ace-ER) in patients with GNE Myopathy (GNEM) did not achi...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase